What it's for (Indications)
- Bacitracin + Lignocaine + Neomycin + Polymyxin B, commonly found in topical formulations such as Healit Skin Ointment, is indicated for the prevention and treatment of minor bacterial skin infections.
- This combination product is specifically formulated for application to minor cuts, scrapes, abrasions, and burns to reduce the risk of infection by susceptible organisms and to provide symptomatic relief from pain and discomfort.
- The broad spectrum of antibacterial activity targets both gram-positive (bacitracin) and gram-negative (neomycin, polymyxin B) bacteria commonly implicated in superficial skin infections.
- Lignocaine, a local anesthetic, acts to quickly alleviate localized pain and itching, improving patient comfort.
- It is important to note that this medication is intended for superficial use only and should not be used for deep or extensive wounds without explicit medical supervision.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For external topical application only. A thin layer of Bacitracin + Lignocaine + Neomycin + Polymyxin B ointment should be applied to the affected skin area one to three times daily, or as directed by a healthcare professional. Before application, the affected area should be thoroughly cleaned and dried to maximize efficacy and prevent further contamination. After applying the ointment, the treated area may be covered with a sterile dressing, if appropriate, to protect the wound and aid in the absorption of the medication. The duration of treatment should generally not exceed 7 days unless advised by a physician, to minimize the risk of bacterial resistance, superinfection, or sensitization. Avoid applying to large areas of the body or for prolonged periods without medical consultation, especially in individuals with compromised skin integrity, as this may increase systemic absorption. |
Safety & Warnings
Common Side Effects
- Adverse reactions to Bacitracin + Lignocaine + Neomycin + Polymyxin B are typically localized and mild, though more severe reactions are possible.
- Common localized side effects include irritation, redness, itching, rash, or swelling at the application site.
- Allergic contact dermatitis, particularly due to neomycin, is a significant concern and can manifest as persistent erythema, papules, vesicles, or weeping, sometimes spreading beyond the application area.
- Sensitization to neomycin may also lead to cross-reactions with other aminoglycoside antibiotics.
- While systemic absorption is minimal with intact skin, application to large areas of broken skin or for prolonged periods can potentially lead to systemic effects.
- These rare systemic effects could include ototoxicity (hearing loss, balance issues) and nephrotoxicity (kidney damage) associated with neomycin and polymyxin B, or central nervous system (CNS) and cardiovascular effects (e.
- g.
- , dizziness, blurred vision, tremors, bradycardia) related to lignocaine absorption.
Serious Warnings
- Black Box Warning: While Bacitracin + Lignocaine + Neomycin + Polymyxin B topical ointment does not carry a formal FDA Black Box Warning, significant caution is warranted due to the potential for serious adverse events upon systemic absorption of its antibiotic components, particularly neomycin and polymyxin B. Applying this combination to large surface areas of the body, deep or puncture wounds, extensive burns, or for prolonged periods, especially in individuals with compromised skin integrity or pre-existing renal impairment, significantly increases the risk of systemic absorption. This systemic exposure can lead to irreversible ototoxicity (hearing loss and vestibular damage), potentially severe nephrotoxicity (kidney damage), and rarely, neurotoxicity (including neuromuscular blockade and respiratory depression). Patients should be carefully monitored for signs of these systemic toxicities, and the product should be discontinued immediately if any such signs appear. Furthermore, severe allergic contact dermatitis, most commonly due to neomycin, can occur, which may be persistent and debilitating. Systemic absorption of lignocaine can also lead to central nervous system and cardiovascular effects, though this is rare with topical application under recommended conditions. Healthcare providers should thoroughly evaluate the risk-benefit profile, especially in vulnerable patient populations.
- Bacitracin + Lignocaine + Neomycin + Polymyxin B is for external use only.
- Avoid contact with eyes, ears, mouth, and other mucous membranes; if accidental contact occurs, rinse thoroughly with water.
- Discontinue use and consult a healthcare provider if irritation, sensitization (e.
- g.
- , worsening rash, itching, redness), or superinfection (new or worsening infection by non-susceptible organisms, such as fungi) develops.
- Prolonged or extensive use may lead to the overgrowth of non-susceptible organisms, including fungi, and may also promote bacterial resistance.
- Caution is advised in patients with extensive burns, deep or puncture wounds, or significant skin damage, as systemic absorption of neomycin and polymyxin B can occur, potentially leading to ototoxicity, nephrotoxicity, or neurotoxicity.
- Patients with pre-existing renal impairment are at an increased risk for systemic toxicities.
- There is a potential for cross-sensitization to other aminoglycoside antibiotics if a patient develops an allergy to neomycin.
- Pregnant or breastfeeding individuals should consult a healthcare professional before use.
How it Works (Mechanism of Action)
This combination ointment exerts its therapeutic effects through the distinct mechanisms of its four active ingredients. **Bacitracin** is a polypeptide antibiotic that primarily inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier molecule bactoprenol pyrophosphate, essential for peptidoglycan formation, thus exhibiting bactericidal activity against many gram-positive bacteria. **Lignocaine (Lidocaine)** is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses, primarily by blocking voltage-gated sodium channels, thereby providing localized pain relief. **Neomycin** is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting bacterial protein synthesis and causing misreading of the mRNA genetic code, leading to the production of non-functional proteins and cell death; it is effective against many gram-negative and some gram-positive bacteria. **Polymyxin B** is another polypeptide antibiotic that acts as a cationic detergent, disrupting the integrity of the bacterial outer and inner cell membranes, particularly in gram-negative bacteria, by binding to lipopolysaccharides (LPS), leading to increased permeability and leakage of intracellular contents, resulting in bactericidal action.
Commercial Brands (Alternatives)
No other brands found for this formula.